Skip to main content
. Author manuscript; available in PMC: 2014 May 27.
Published in final edited form as: Bone. 2007 Oct 17;42(2):332–340. doi: 10.1016/j.bone.2007.10.004

Fig. 1.

Fig. 1

Fabrication of autologous stem cell-based implants with controlled delivery of TGFβ3. Aspiration of autologous bone marrow (a) and isolation of mononucleated and adherent cells that will populate the engineered cranial suture (b). (c) Differentiation of MSCs into cells of several tissue-specific lineages including osteoblasts. (d) Encapsulation of TGFβ3 in poly(dl-lactic-co-glycolic acid) (PLGA) microspheres that are biocompatible and biodegradable for controlled release. (e) and (f) Loading of microencapsulated TGFβ3 (e) and autologous cells (f) in a biocompatible collagen sponge carrier. (g) Implantation of engineered construct into the osteotomy site of synostosed cranial suture in the same corresponding rat that earlier donated bone marrow sample.